Life Scientist > Biotechnology

Give it a myth: the big assumptions about GM

05 July, 2002 by Melissa Trudinger

Several myths, misconceptions and assumptions about genetically modified organisms and food have made their way into the public arena. What doesn't help the average punter to get a grip on the science is that there are huge swathes of information available, from scientists, policy-makers, lobbyists and industry. And for every opinion exists its opposite.


New research eases strain on artificial muscle

05 July, 2002 by Tanya Hollis

Australian researchers have created salt-based liquids that improve the performance of artificial muscle by thousands of times.


Shareholders back MicroMedical name change

05 July, 2002 by Tanya Hollis

A proposed name change for artificial heart developer MicroMedical Industries has gained the backing of nearly all its shareholders.


Ambri re-brands in lead-up to diagnostic launch

05 July, 2002 by Melissa Trudinger

Ambri has launched a corporate re-branding campaign as it prepares to launch testing of its SensiDx point-of-care diagnostic system in Australian hospitals.


Biotechs fear OGTR cost recovery could quash R&D

05 July, 2002 by Melissa Trudinger

Plant biotechnologists in Australia are concerned that implementation of a full cost recovery scheme for the Office of the Gene Technology Regulator will make the cost of developing new GM crop varieties too expensive for small biotechnology companies and public research institutions to consider.


Chemeq's drug approved for sale in South Africa

04 July, 2002 by Melissa Trudinger

Chemeq has announced that it has received its first regulatory approval for sale of its veterinary drug CHEMEQ polymeric antimicrobial in South Africa.


Views on GM polarised: WA survey

04 July, 2002 by Pete Young

A Western Australian government survey of public and industry views has revealed strongly-polarised views about the costs and benefits of introducing genetically modified crops, says Agriculture Minister Kim Chance.


Federal funding recieved for foot and mouth monitoring

03 July, 2002 by Melissa Trudinger

CSIRO's Australian Animal Health Laboratory has received $1 million from the Federal government to improve systems for prevention of foot and mouth disease outbreaks in Australia.


CSIRO and GRDC team up to study grain crop problems

03 July, 2002 by Melissa Trudinger

CSIRO Entomology and the Grains Research and Development Corporation have signed a $20 million agreement for a research alliance focusing on the pests and diseases affecting Australia's grain industries.


Virax files prostate cancer therapy patent

02 July, 2002 by Tanya Hollis

Immune-based drug developer Virax Holdings has announced it had filed a patent relating to a potential new prostate cancer therapy.


GTG claims progress made in AIDS research

02 July, 2002 by Melissa Trudinger

Melbourne company Genetic Technologies has reported that it is making good progress with its AIDS research project.


Peptech seeks approval for dog contraceptive

02 July, 2002 by Tanya Hollis

Peptech's animal health division has applied to register its medication to control fertility and reproductive behaviour in dogs.


Peplin overcomes scale-up hurdles and exports cancer drug

02 July, 2002 by Pete Young

Peplin Biotech has shipped the first significant quantity of its lead anti-cancer drug PEP 005 after a year-long effort which it says has "cracked the back" of any manufacturing problems.


Acrux raises $9.8m to speed drug delivery program

02 July, 2002 by Tanya Hollis

Novel drug delivery company Acrux has raised $9.8 million through the sale of 10 per cent of its stock to Queensland Investment Corporation.


Eiffel signs new drug delivery agreement

01 July, 2002 by Tanya Hollis

Eiffel Technologies has signed a new agreement with specialist UK drug company Profile Therapeutics to investigate delivery methods for an undisclosed pharmaceutical compound.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd